No Data
Retail Investors in Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 9.7% Last Week
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Luoxin Pharmaceuticals Group Stock (002793.SZ): The hydrochloride levalbuterol nebulization solution has obtained the Pharmaceutical registration certificate.
On March 14th, Gelonghui reported that Luoxin Pharmaceuticals Group Stock (002793.SZ) announced that its subsidiary, Luoxin Anruoweita Pharmaceuticals (Chengdu) Co., Ltd., recently received the Drug Registration Certificate for Salbutamol Hydrochloride Nebulized Inhalation Solution issued by the National Medical Products Administration. Salbutamol is a β2-adrenergic receptor agonist, mainly stimulating the β2-adrenergic receptors on the smooth muscle of the respiratory tract, resulting in the activation of adenylate cyclase and increasing the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cAMP). The increase in cAMP activates protein kinase A, protein kinase.
Luoxin Pharmaceuticals Gets Nod to Trial LX22001 Injection for Another Type of Disorder; Shares Up 7%
Luoxin Pharmaceuticals Group Stock (002793.SZ): Approval granted for clinical trials of the new indication for LX22001 injection.
On March 11, the company announced that Luoxin Pharmaceuticals Group Stock (002793.SZ) announced that its subsidiary, ShanDong Luoxin Pharmaceuticals Group Stock Co., Ltd., and Luoxin Pharmaceuticals (Shanghai) Co., Ltd. received the "Notification of Approval for Clinical Trials" issued by the National Medical Products Administration for the new indication of injectable LX22001, which is "Prevention of Stress Ulcer Bleeding in Severe Patients." Injectable LX22001 is a potassium-competitive acid blocker (P-CAB).
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) 29% Share Price Surge Not Quite Adding Up
